What Is Eloralintide?

Eloralintide, previously identified by the development code LY3841136, is a synthetic, long-acting peptide drug candidate designed to activate amylin receptors. Eli Lilly is developing it primarily as a potential treatment for obesity and chronic weight management. In the clinical program reported to date, eloralintide has been administered by subcutaneous injection on a once-weekly schedule.

Eloralintide belongs to a different pharmacologic family from semaglutide, tirzepatide, retatrutide, and other incretin-based agents. It does not principally work by activating the glucagon-like peptide-1 receptor. Instead, it attempts to reproduce selected effects of the pancreatic hormone amylin, especially enhanced satiation, reduced calorie intake, and regulation of meal-related signaling.

The candidate has attracted attention because Phase 2 data showed substantial mean weight reduction as monotherapy, including a reported mean reduction of 20.1% at 48 weeks in the 9 mg arm under the trial’s efficacy estimand. Importantly, these findings come from an investigational study and do not establish that eloralintide is approved, appropriate for general use, or proven safe over the long term.

Amylin Biology: The Physiologic System Eloralintide Is Designed to Mimic

Amylin, also called islet amyloid polypeptide, is a 37-amino-acid peptide hormone produced by pancreatic beta cells. It is normally co-secreted with insulin in response to nutrient intake. Whereas insulin is central to glucose uptake and metabolic storage, amylin contributes to the coordination of how quickly nutrients enter circulation and how much food is consumed.

Major physiologic actions associated with native amylin

• Satiation: Amylin contributes to meal termination, helping the nervous system register that enough food has been consumed.
• Reduced food intake: Pharmacologic amylin signaling can decrease caloric consumption, particularly through smaller meals.
• Slower gastric emptying: Native amylin can slow movement of food from the stomach into the small intestine, although the magnitude and persistence of this effect may depend on dose, receptor profile, and treatment duration.
• Suppression of inappropriate post-meal glucagon: Amylin helps coordinate glucose regulation by limiting excessive glucagon release after eating.
• Central energy-balance signaling: Amylin-responsive circuits in the hindbrain and hypothalamus communicate with broader networks governing appetite, reward, nausea, autonomic function, and energy homeostasis.

Native human amylin is poorly suited for simple therapeutic use because it has a short circulating half-life and a tendency to aggregate. Drug developers therefore modify amylin-like peptides to improve solubility, stability, receptor behavior, and duration of action.

Receptor Profile and Selectivity

Amylin pharmacology is more complicated than a single receptor binding to a single hormone. Functional amylin receptors are formed when the calcitonin receptor associates with one of several receptor activity-modifying proteins, commonly abbreviated RAMPs. Different combinations generate receptor subtypes with distinct pharmacologic characteristics.

Published translational work reported that eloralintide preferentially activated the human AMY1 receptor in vitro, with substantially lower potency at the isolated calcitonin receptor and AMY3 receptor under the tested conditions. The exact functional meaning of selectivity measured in engineered cell assays must be interpreted cautiously: receptor expression, coupling efficiency, species differences, assay design, and tissue context can all alter apparent potency.

The development hypothesis is that more selective amylin-receptor activation may preserve appetite and weight effects while limiting receptor activity that could contribute to undesirable gastrointestinal or aversive responses. This remains a hypothesis under clinical evaluation rather than a conclusively proven receptor-to-side-effect relationship.

Structure, Sequence, Formula, and Molecular Design

Eloralintide is described publicly as a long-acting amylin analog or amylin receptor agonist. Its clinical behavior indicates that it has been engineered to last far longer than native amylin, permitting once-weekly dosing in clinical trials.

Long-acting peptide design commonly involves one or more strategies such as amino-acid substitutions that resist enzymatic cleavage, modifications that reduce aggregation, chemical conjugation that promotes albumin binding, or other changes that slow renal clearance. The published eloralintide literature describes a long pharmacokinetic profile, but publicly accessible clinical summaries do not provide enough information to responsibly reconstruct a verified full sequence, exact elemental formula, or definitive molecular weight from primary sources.

Mechanism of Action

Eloralintide acts as an agonist at amylin receptor complexes. Agonism means the molecule binds to a receptor and activates signaling rather than merely blocking it. Amylin receptors are class B G-protein-coupled receptor complexes. Their activation can increase intracellular cyclic AMP and initiate downstream neural and metabolic responses.

1. Promotion of satiation

One of the most important expected effects is stronger meal-related fullness. Satiation refers to the processes that bring an ongoing meal to an end, whereas satiety describes the reduced desire to eat between meals. Amylin signaling can influence both, but its classic physiologic role is strongly associated with meal termination.

2. Reduced energy intake

By strengthening fullness signals and reducing appetite, eloralintide can lower total calorie intake. The weight reduction observed in trials is therefore understood primarily as a consequence of sustained negative energy balance rather than direct chemical “fat burning.”

3. Hindbrain and hypothalamic signaling

Amylin-responsive neurons are found in areas including the area postrema and nucleus of the solitary tract, which communicate with hypothalamic and limbic regions. These networks integrate gastrointestinal, hormonal, autonomic, and reward-related information. Because the area postrema also participates in nausea and emesis signaling, successful amylin-drug design requires a balance between appetite effects and tolerability.

4. Gastric and postprandial effects

Amylin biology includes delayed gastric emptying and modulation of post-meal glucagon. The relative contribution of these effects to eloralintide-induced weight loss has not been completely quantified. Long-term body-weight outcomes cannot be attributed to gastric emptying alone.

5. Potential differences from incretin signaling

GLP-1 receptor agonists and amylin agonists both reduce food intake, but they begin at different receptors and engage partly distinct neural circuits. This creates interest in eloralintide both as a stand-alone alternative and as a combination partner with incretin therapy.

Preclinical Research

Translational studies evaluated eloralintide in receptor assays and animal models before and alongside clinical development. In diet-induced obese rats, repeated administration produced dose-dependent reductions in food intake and body weight. The reported loss was driven predominantly by fat mass rather than lean mass in those animal experiments.

Investigators also used conditioned taste avoidance paradigms, which are often employed in rodents as an indirect measure of visceral malaise or aversive effects. Eloralintide reportedly produced less conditioned taste avoidance than cagrilintide under the specific experimental conditions used. This finding supports the hypothesis of differentiated tolerability, but animal taste-avoidance experiments cannot directly predict nausea rates or treatment persistence in humans.

Nonhuman primate and pharmacokinetic research supported extended exposure compatible with weekly administration. Published clinical pharmacology modeling later characterized eloralintide as a long-acting molecule with pharmacokinetic behavior suitable for once-weekly dosing.

Phase 1 Clinical Research

A randomized, placebo-controlled, participant- and investigator-blinded first-in-human study evaluated single ascending subcutaneous doses in healthy participants. Public reports describe doses ranging from 0.04 mg to 12 mg. The study focused on safety, tolerability, pharmacokinetics, pharmacodynamics, appetite-related effects, and short-term body-weight change.

Eloralintide demonstrated prolonged exposure consistent with weekly administration. Early proof-of-concept reports showed dose-related effects on appetite and body weight. At the upper end of the studied dose range, early presentations reported double-digit percentage weight reduction over approximately 12 weeks in a small investigational cohort. Such early results are hypothesis-generating because Phase 1 trials are limited in size, duration, and representativeness.

Why Phase 1 results must be interpreted cautiously

• Participant numbers are small compared with pivotal trials.
• Healthy-volunteer populations may not reflect people with obesity-related disease.
• Short follow-up cannot establish long-term safety or weight-loss durability.
• Early cohorts may use fixed doses or escalation patterns unlike later clinical practice.
• Uncontrolled comparisons with other drugs are unreliable.

Phase 2 Trial: Design and Weight-Loss Findings

The principal Phase 2 monotherapy study, identified as NCT06230523, was a 48-week randomized, double-blind, placebo-controlled trial conducted in the United States. It enrolled 263 adults with obesity, or overweight with at least one weight-related comorbidity, who did not have type 2 diabetes.

Participants were assigned to placebo, fixed weekly doses of 1 mg, 3 mg, 6 mg, or 9 mg, or to dose-escalation regimens that progressed to 9 mg. The primary objective was superiority to placebo for percentage change in body weight from baseline at week 48.

These values were reported using the trial’s efficacy estimand, which estimates the effect that would have occurred had randomized participants remained on study intervention, allowing for specified interruptions or dose modifications. Efficacy-estimand results should not be confused with a simple observed average among every randomized participant regardless of discontinuation.

Dose-response pattern

The fixed-dose arms showed a clear dose-response relationship: higher doses were associated with greater mean weight reduction. The two escalation strategies also produced substantial weight loss, although their results were not identical. Differences may reflect time spent at lower doses, tolerability-driven interruptions, sample size, and the specific escalation schedule.

Cardiometabolic findings

In addition to body weight and body-mass index, Lilly reported improvements across waist circumference, blood pressure, lipid measures, glycemic control, and inflammatory markers. These secondary outcomes are biologically plausible consequences of weight reduction, but the degree to which eloralintide provides benefits independent of weight loss remains uncertain.

Safety, Adverse Events, and Tolerability

The most frequently reported adverse events in the Phase 2 study were gastrointestinal symptoms and fatigue. Events were generally described as mild to moderate and occurred more often in higher-dose groups. Slower escalation reduced the frequency of these events, while the 1 mg and 3 mg arms reportedly had adverse-event incidence closer to placebo.

Adverse-event categories of interest

• Nausea and other gastrointestinal symptoms: Expected concerns for agents acting in appetite and gastric-control pathways.
• Vomiting: Particularly relevant to area-postrema signaling and dose-escalation design.
• Diarrhea or constipation: Potential consequences of altered gastrointestinal motility and intake.
• Fatigue: Reported more frequently at higher doses in the Phase 2 program.
• Reduced appetite: A pharmacodynamic effect that can become adverse when excessive or accompanied by inadequate nutrition.
• Injection-site reactions: A general consideration for subcutaneous peptide products.

What remains unknown

Phase 2 studies are not large enough to rule out uncommon or delayed adverse effects. Long-term questions include gallbladder events associated with rapid weight loss, pancreatitis signals, clinically significant dehydration, effects on heart rate or blood pressure, nutritional insufficiency, psychiatric outcomes, immunogenicity, and safety in people with severe gastrointestinal disease, advanced kidney or liver disease, pregnancy, or multiple interacting medications.

Because eloralintide is not approved, there is no finalized prescribing information, contraindication list, standardized commercial titration schedule, or post-marketing safety database.

Body Composition and the “Quality of Weight Loss” Question

One of the most important issues in modern obesity pharmacotherapy is not only how much weight is lost, but what tissue accounts for that loss. Any substantial weight reduction can include both fat mass and lean mass. Preservation of skeletal muscle matters for strength, mobility, glucose disposal, resting energy expenditure, and long-term functional health.

In rodent experiments, eloralintide-induced weight loss was reported to come predominantly from fat mass. That finding has contributed to interest in the candidate’s potential “quality of weight loss.” However, animal body-composition data should not be treated as proof of superior muscle preservation in humans.

To establish a meaningful human advantage, clinical trials would need carefully controlled measurements such as dual-energy X-ray absorptiometry, magnetic resonance imaging, strength testing, physical-function outcomes, dietary assessment, and comparisons adjusted for total weight loss. Public Phase 2 summaries do not yet establish that eloralintide preserves lean tissue better than GLP-1 or dual-incretin drugs.

How Eloralintide Compares With Other Metabolic Drug Classes

Eloralintide versus GLP-1 therapies

Both pathways can reduce appetite and body weight, but receptor targets differ. This may lead to differences in meal pattern, nausea profile, gastric effects, glucose lowering, cardiovascular biology, and suitability for combination treatment. Direct head-to-head randomized trials are necessary before claiming that eloralintide is more effective or better tolerated than a particular approved incretin therapy.

Combination with tirzepatide

Amylin and incretin pathways are potentially complementary. Tirzepatide activates GIP and GLP-1 receptors, while eloralintide activates amylin receptors. A combination could theoretically produce greater appetite suppression or allow different dose balances, but it may also intensify gastrointestinal effects or excessive energy restriction. Lilly has initiated studies evaluating eloralintide alone and with tirzepatide, including research in participants with obesity or overweight and type 2 diabetes.

Phase 3 Development Program

Following the positive Phase 2 findings, Lilly advanced eloralintide into Phase 3 development. Public trial registrations describe large, randomized, placebo-controlled studies in adults with obesity or overweight, including separate populations with and without type 2 diabetes.

Phase 3 studies are designed to provide a broader understanding of efficacy, tolerability, discontinuation, metabolic outcomes, and safety over a longer period. Regulatory approval would still require successful completion and review of the full clinical and manufacturing package.

Limitations of the Current Evidence

1. No regulatory approval: Eloralintide remains experimental.
2. Limited long-term data: Forty-eight-week Phase 2 results do not establish multi-year durability or safety.
3. Small safety database: A few hundred exposed participants cannot reliably identify rare adverse events.
4. No definitive cardiovascular-outcomes evidence: Improvements in risk markers are not equivalent to proof of fewer heart attacks, strokes, or deaths.
5. Incomplete structural disclosure: Exact sequence and chemistry should not be asserted without authoritative documentation.
6. Insufficient head-to-head comparisons: Cross-trial comparisons with semaglutide, tirzepatide, cagrilintide, petrelintide, or retatrutide are confounded by different populations, durations, estimands, and trial designs.
7. Body-composition claims remain preliminary: Animal findings do not prove superior lean-mass preservation in humans.
8. Maintenance after discontinuation is unknown: Appetite and weight regain after stopping therapy require dedicated study.

Analytical Testing and COA Interpretation for Eloralintide Research Material

Because eloralintide is investigational and its exact reference standard may not be broadly available, identity testing presents special challenges. A certificate of analysis should never be treated as reliable merely because it lists a high “purity” percentage.

Analytical methods that may be relevant

• LC-MS or high-resolution mass spectrometry: Used to evaluate molecular mass and support identity. Interpretation requires an authentic target mass and awareness of adducts, charge states, counterions, and conjugated modifications.
• Reverse-phase HPLC or UPLC: Used to estimate chromatographic purity and detect related peptide impurities. Area percentage is not the same as peptide content.
• Amino-acid analysis: Can support peptide-content determination but may not independently confirm sequence or modification position.
• Peptide mapping or tandem mass spectrometry: More informative for sequence confirmation and localization of modifications.
• Water determination: Karl Fischer analysis can quantify moisture, which affects apparent material weight.
• Residual solvents: Headspace gas chromatography may be used when solvents are present from synthesis or purification.
• Counterion analysis: Trifluoroacetate, acetate, chloride, or other counterions can materially affect gross vial mass.
• Endotoxin and bioburden testing: Relevant to laboratory handling but not proof of sterility.
• Sterility testing: Requires validated compendial methods and appropriate sampling; a sterility statement is different from endotoxin testing.

How to read a COA critically

Frequently Asked Questions

Is eloralintide a GLP-1 drug?

No. It is designed as a selective amylin receptor agonist. Its appetite and weight effects overlap functionally with GLP-1 therapies, but the primary receptor mechanism is different.

Is eloralintide a peptide?

Yes. It is described as a modified, long-acting amylin analog and peptide receptor agonist.

Is eloralintide FDA approved?

No. As of July 2026, it remains investigational and is being evaluated in Phase 3 clinical trials.

Who developed eloralintide?

Eli Lilly and Company is developing eloralintide under the research code LY3841136.

How much weight was lost in Phase 2?

At 48 weeks, reported mean weight reductions ranged from 9.5% in the 1 mg arm to 20.1% in the 9 mg arm, compared with 0.4% for placebo, using the efficacy estimand.

Does eloralintide preserve muscle?

Animal studies reported predominantly fat-mass loss, but current public human evidence does not establish superior muscle preservation. Controlled human body-composition and functional data are required.

What were the most common side effects?

Gastrointestinal symptoms and fatigue were the most commonly reported adverse events in Phase 2, particularly at higher doses. Slower escalation was associated with improved tolerability.

Why is receptor selectivity important?

Researchers hypothesize that selective activation of preferred amylin receptor complexes may retain weight-loss efficacy while reducing unwanted aversive or gastrointestinal signaling. The clinical relevance of this selectivity is still being established.

Could eloralintide be combined with tirzepatide?

Clinical research is evaluating the combination. The rationale is complementary amylin and incretin signaling, but efficacy and safety must be established in randomized trials.

Is a research-vendor product equivalent to Lilly’s clinical drug?

Not necessarily. A product using the name eloralintide may lack verified identity, sequence, modification pattern, formulation, purity, content, stability, or bioactivity. Only material manufactured and controlled within the authorized clinical program can be assumed to match the investigational drug used in trials.

Conclusion

Eloralintide is one of the most important emerging non-incretin candidates in obesity research. By selectively activating amylin receptors, it targets a physiologic satiation pathway that is related to—but distinct from—GLP-1 and GIP signaling. The reported Phase 2 findings demonstrate that weekly amylin agonism can produce substantial weight reduction as monotherapy, reaching a mean 20.1% reduction at 48 weeks in the highest fixed-dose arm under the efficacy estimand.

The program is promising, but the scientific picture remains incomplete. Phase 3 trials must confirm efficacy in larger and more diverse populations, define tolerability and discontinuation patterns, identify uncommon safety signals, clarify body-composition outcomes, and determine whether combination therapy offers a favorable benefit-risk balance. Until regulatory review is complete, eloralintide should be described accurately as an investigational peptide drug—not as an approved obesity treatment.

Selected References and Clinical-Trial Sources

1. Briere DA, Long A, Bullock DM, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: translational pharmacology and first-in-human evaluation. Molecular Metabolism. 2025. PubMed PMID: 41109426.
2. Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity or overweight: a Phase 2 randomized, double-blind, placebo-controlled trial. The Lancet. 2025. PubMed PMID: 41207310.
3. Bhattachar SN, Tham L-S, Tidemann-Miller B, et al. Eloralintide, a selective, long-acting amylin receptor agonist: population pharmacokinetics and exposure-response analysis. 2026. PubMed PMID: 41559929.
4. Eli Lilly and Company. “Lilly’s selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study.” News release, November 6, 2025.
5. ClinicalTrials.gov. NCT06230523. Phase 2 study of eloralintide in adults with obesity or overweight without type 2 diabetes.
6. ClinicalTrials.gov. NCT07321886. Phase 3 study of eloralintide in adults with obesity or overweight without type 2 diabetes.
7. ClinicalTrials.gov. NCT07282600. Phase 3 study of eloralintide in adults with obesity or overweight and type 2 diabetes.
8. ClinicalTrials.gov. NCT07215559. Study of macupatide and eloralintide, alone or in combination, in adults with obesity or overweight and type 2 diabetes.
9. ClinicalTrials.gov. NCT07353931. Eloralintide studies in adults with obesity or overweight and knee osteoarthritis pain.
10. Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: pharmacology, physiology, and clinical potential. Pharmacological Reviews. 2015;67(3):564-600.
11. Boyle CN, Lutz TA, Le Foll C. Amylin—its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity. Molecular Metabolism. 2018;8:203-210.
12. Lutz TA. Control of energy homeostasis by amylin. Cellular and Molecular Life Sciences. 2012;69:1947-1965.
13. Roth JD, Maier H, Chen S, Roland BL. Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. Archives of Neurology. 2009;66(3):306-310.
14. Bailey CJ, et al. Long-acting amylin-related peptides as therapies for obesity and metabolic disease. 2026. PubMed PMID: 41747885.

Evidence status reviewed through July 15, 2026. Trial registrations and development timelines may change as studies are amended or completed.